NCT02138682

Validation of DaTscan for Detection of Parkinson Disease Related Disorders

Validation of DaTscan for Detection of Parkinsonian Disease and Related Disorders Using Neuropathologically-confirmed Parkinson Disease From Human Brain Tissue

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 20 (estimated)
• Sponsor: Wisconsin Institute for Neurologic and Sleep Disorders S.C. · Industry
• Sex: All
• Age: 75 Years
• Healthy volunteers: Not accepted

Summary

This investigator initiated trial is designed to measure the accuracy of diagnosis of Parkinson disease through the use of DaTscan. Currently, DaTscan is FDA approved to measure dopamine transporter densities in human tissue. This measurement can assist in distinguishing between Essential Tremor and Parkinsonian Syndromes (idiopathic Parkinson disease, Progressive Supranuclear Palsy, Multi Systems Atrophy, etc). This study will compare both clinical diagnosis of symptoms and the results of the scan to the pathological diagnosis received at time of death. Patients will be registered in the Parkinson Research Institute's brain donation program, receive a clinical diagnosis of Parkinson disease, have their brain scanned using DaTscan, and donate their tissue for research and autopsy purposes. The hypothesis of the study is that DaTscan will diagnosis Idiopathic Parkinson Disease as accurately as a clinician.

Conditions

• Parkinson Disease
• Movement Disorders

Interventions

Type	Name	Description
DRUG	l-123 Ioflupane	5 millicuries of Ioflupane

Timeline

• Start date: 2014-07-01
• Primary completion: 2016-04-01
• First posted: 2014-05-14
• Last updated: 2014-07-16

Locations

2 sites across 1 country: United States